This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...